

Morteza Akbari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11276211/publications.pdf>

Version: 2024-02-01

20
papers

214
citations

1307594

7
h-index

1058476

14
g-index

20
all docs

20
docs citations

20
times ranked

222
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential anti-inflammatory effect of anti-HMGB1 in animal models of ICH by downregulating the TLR4 signaling pathway and regulating the inflammatory cytokines along with increasing HO1 and NRF2. <i>European Journal of Pharmacology</i> , 2022, 915, 174694.	3.5	3
2	MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers. <i>Genes and Diseases</i> , 2022, 9, 849-867.	3.4	13
3	Anastasis: cell recovery mechanisms and potential role in cancer. <i>Cell Communication and Signaling</i> , 2022, 20, .	6.5	5
4	Association between microRNAs and chemoresistance in pancreatic cancer: Current knowledge, new insights, and forthcoming perspectives. <i>Pathology Research and Practice</i> , 2022, 236, 153982.	2.3	2
5	Potential of chimeric antigen receptor (<sc>CAR</sc>)â€ redirected immune cells in breast cancer therapies: Recent advances. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4137-4156.	3.6	3
6	A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview. <i>Journal of Ovarian Research</i> , 2022, 15, .	3.0	5
7	Prognostic and Diagnostic Values of miR-506 and SPON 1 in Colorectal Cancer with Clinicopathological Considerations. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 125-129.	1.3	16
8	miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4. <i>International Immunopharmacology</i> , 2021, 92, 107355.	3.8	36
9	Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. <i>Stem Cell Research and Therapy</i> , 2021, 12, 200.	5.5	25
10	Upâ€ regulation of KISS1 as a novel target of Letâ€7i in melanoma serves as a potential suppressor of migration and proliferation in vitro. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 6864-6873.	3.6	5
11	HSP90 inhibitor modulates HMGA1 and HMGB2 expression along with cell viability via NF-KB signaling pathways in melanoma in-vitro. <i>Gene Reports</i> , 2021, 24, 101205.	0.8	5
12	Restoration of miR-124 serves as a promising therapeutic approach in CRC by affecting CDK6 which is itself a prognostic and diagnostic factor. <i>Gene Reports</i> , 2021, 24, 101274.	0.8	1
13	CD133: An emerging prognostic factor and therapeutic target in colorectal cancer. <i>Cell Biology International</i> , 2020, 44, 368-380.	3.0	31
14	<sc>miR</sc>â€143 acts as an inhibitor of migration and proliferation as well as an inducer of apoptosis in melanoma cancer cells in vitro. <i>IUBMB Life</i> , 2020, 72, 2034-2044.	3.4	28
15	Dysregulation of miR-27a and SMAD2 can be a reliable indicator in the prognosis and diagnosis of CRC as well as in response to chemotherapy drugs. <i>Gene Reports</i> , 2020, 21, 100844.	0.8	5
16	Altered expression levels of miR-212, miR-133b and miR-27a in tongue squamous cell carcinoma (TSCC) with clinicopathological considerations. <i>Gene Reports</i> , 2020, 19, 100622.	0.8	0
17	Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2020, 12, 88-94.	0.8	1
18	A survey on prognosis of anterior cruciate ligament (ACL) reconstruction surgeries following fixed loop and adjustable loop methods. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2020, 12, 173-177.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Dysregulated microRNAs in colorectal carcinogenesis: New insight to cell survival and apoptosis regulation. <i>Journal of Cellular Physiology</i> , 2019, 234, 21683-21693.	4.1	26
20	Effects of CD133 Silencing on Survival and Migration of HT-29 Colorectal Cancer Cells. <i>Iranian Journal of Immunology</i> , 2019, 16, 246-257.	0.6	4